The reiteration of a Neutral rating and maintenance of a $330 price target by a reputable analyst firm like HC Wainwright & Co. suggests stability in the analyst's view towards Karuna Therapeutics. This stability is likely to have a neutral short-term impact on the stock price, as it does not introduce new positive or negative information but confirms the existing valuation and outlook.